Is BRNS or TNFA more profitable?

Barinthus Biotherapeutics' return on equity of -63.83% beat TNF Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -63.83% -48.77% TNF Pharmaceuticals N/A -69.21% -33.98%

Do analysts rate BCTX or TNFA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, BCTX or TNFA?

Briacell Therap is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Briacell Therap N/A N/A -$26.31M -$7.92 N/A TNF Pharmaceuticals N/A N/A -$23.36M -$231.00 N/A

Is BCTX or TNFA more profitable?

TNF Pharmaceuticals' return on equity of -69.21% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% TNF Pharmaceuticals N/A -69.21% -33.98%

Do analysts rate CPHI or TNFA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer TNFA or EVAX?

Evaxion A/S has a consensus target price of $11.00, indicating a potential upside of 222.58%. Given Evaxion A/S's stronger consensus rating and higher probable upside, analysts plainly believe Evaxion A/S is more favorable than TNF Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is TNFA or EVAX more profitable?

TNF Pharmaceuticals' return on equity of -69.21% beat Evaxion A/S's return on equity. Company Net Margins Return on Equity Return on Assets TNF Pharmaceuticals N/A -69.21% -33.98% Evaxion A/S N/A -73.56% -37.45%

Do analysts prefer PLRZ or TNFA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, PLRZ or TNFA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A TNF Pharmaceuticals N/A N/A -$23.36M -$231.00 N/A

Is PLRZ or TNFA more profitable?

Polyrizon's return on equity of 0.00% beat TNF Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A TNF Pharmaceuticals N/A -69.21% -33.98%

TNF Pharmaceuticals (TNFA) Competitors

$3.85 -0.11 (-2.78%)

As of 07/2/2026

Compare

TNFA vs. BRNS, BCTX, CPHI, EVAX, and PLRZ

Should you buy TNF Pharmaceuticals stock or one of its competitors? MarketBeat compares TNF Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TNF Pharmaceuticals include Barinthus Biotherapeutics (BRNS), Briacell Therap (BCTX), China Pharma (CPHI), Evaxion A/S (EVAX), and Polyrizon (PLRZ). These companies are all part of the "pharmaceutical products" industry.

How does TNF Pharmaceuticals compare to Barinthus Biotherapeutics?

Barinthus Biotherapeutics (NASDAQ:BRNS) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Barinthus Biotherapeutics currently has a consensus price target of $4.00, indicating a potential upside of 545.06%. Given Barinthus Biotherapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Barinthus Biotherapeutics is more favorable than TNF Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Barinthus Biotherapeutics had 1 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 1 mentions for Barinthus Biotherapeutics and 0 mentions for TNF Pharmaceuticals. Barinthus Biotherapeutics' average media sentiment score of 0.00 equaled TNF Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
TNF Pharmaceuticals	Neutral

Barinthus Biotherapeutics' return on equity of -63.83% beat TNF Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%
TNF Pharmaceuticals	N/A	-69.21%	-33.98%

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are owned by institutional investors. 8.5% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

TNF Pharmaceuticals has lower revenue, but higher earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.69	-$66.43M	-$1.29	N/A
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A

Barinthus Biotherapeutics has a beta of -0.41, suggesting that its stock price is 141% less volatile than the broader market. Comparatively, TNF Pharmaceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market.

Summary

Barinthus Biotherapeutics beats TNF Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does TNF Pharmaceuticals compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

In the previous week, Briacell Therap's average media sentiment score of 0.00 equaled TNF Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Briacell Therap	Neutral
TNF Pharmaceuticals	Neutral

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are held by institutional investors. 0.7% of Briacell Therap shares are held by insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Briacell Therap is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TNF Pharmaceuticals' return on equity of -69.21% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
TNF Pharmaceuticals	N/A	-69.21%	-33.98%

Briacell Therap has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, TNF Pharmaceuticals has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

Summary

TNF Pharmaceuticals beats Briacell Therap on 5 of the 8 factors compared between the two stocks.

How does TNF Pharmaceuticals compare to China Pharma?

China Pharma (NYSE:CPHI) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TNF Pharmaceuticals has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat TNF Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
TNF Pharmaceuticals	N/A	-69.21%	-33.98%

9.6% of TNF Pharmaceuticals shares are owned by institutional investors. 6.4% of China Pharma shares are owned by company insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

China Pharma has higher revenue and earnings than TNF Pharmaceuticals. China Pharma is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	7.29	-$3.08M	-$0.55	N/A
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A

In the previous week, China Pharma's average media sentiment score of 0.00 equaled TNF Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
China Pharma	Neutral
TNF Pharmaceuticals	Neutral

China Pharma has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, TNF Pharmaceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market.

Summary

China Pharma beats TNF Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does TNF Pharmaceuticals compare to Evaxion A/S?

TNF Pharmaceuticals (NASDAQ:TNFA) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

TNF Pharmaceuticals' return on equity of -69.21% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TNF Pharmaceuticals	N/A	-69.21%	-33.98%
Evaxion A/S	N/A	-73.56%	-37.45%

9.6% of TNF Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 0.5% of TNF Pharmaceuticals shares are owned by company insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

TNF Pharmaceuticals has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

In the previous week, Evaxion A/S had 1 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 1 mentions for Evaxion A/S and 0 mentions for TNF Pharmaceuticals. TNF Pharmaceuticals' average media sentiment score of 0.00 equaled Evaxion A/S'saverage media sentiment score.

Company	Overall Sentiment
TNF Pharmaceuticals	Neutral
Evaxion A/S	Neutral

Evaxion A/S has a consensus target price of $11.00, indicating a potential upside of 222.58%. Given Evaxion A/S's stronger consensus rating and higher probable upside, analysts plainly believe Evaxion A/S is more favorable than TNF Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Evaxion A/S has higher revenue and earnings than TNF Pharmaceuticals. Evaxion A/S is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A
Evaxion A/S	$7.53M	3.78	-$7.71M	-$1.47	N/A

Summary

Evaxion A/S beats TNF Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does TNF Pharmaceuticals compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Polyrizon's return on equity of 0.00% beat TNF Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
TNF Pharmaceuticals	N/A	-69.21%	-33.98%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.6% of TNF Pharmaceuticals shares are held by institutional investors. 0.5% of TNF Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Polyrizon has a beta of -1.59, suggesting that its share price is 259% less volatile than the broader market. Comparatively, TNF Pharmaceuticals has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market.

In the previous week, Polyrizon had 8 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 8 mentions for Polyrizon and 0 mentions for TNF Pharmaceuticals. Polyrizon's average media sentiment score of 1.05 beat TNF Pharmaceuticals' score of 0.00 indicating that Polyrizon is being referred to more favorably in the media.

Company	Overall Sentiment
Polyrizon	Positive
TNF Pharmaceuticals	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A

Summary

Polyrizon beats TNF Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Get TNF Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNFA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNFA vs. The Competition

Export

Metric	TNF Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.11M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	-0.02	20.06	28.02	24.70
Price / Sales	N/A	360.34	540.55	99.42
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	0.01	4.32	10.96	6.46
Net Income	-$23.36M	$64.45M	$3.57B	$337.01M
7 Day Performance	7.54%	2.97%	2.12%	1.69%
1 Month Performance	1.58%	6.83%	5.25%	3.81%
1 Year Performance	-67.09%	29.07%	33.29%	23.90%

TNF Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNFA TNF Pharmaceuticals	N/A	$3.85 -2.8%	N/A	-67.1%	$7.11M	N/A	N/A	6
BRNS Barinthus Biotherapeutics	1.7519 of 5 stars	$0.66 -0.1%	$4.00 +506.1%	-36.4%	$26.99M	$14.97M	N/A	107	News Coverage Gap Up
BCTX Briacell Therap	0.5648 of 5 stars	$3.24 +4.4%	N/A	-88.8%	$26.97M	N/A	N/A	8	Gap Up
CPHI China Pharma	N/A	$0.66 +5.3%	N/A	-61.0%	$26.75M	$3.99M	N/A	250	Gap Down
EVAX Evaxion A/S	2.2563 of 5 stars	$3.10 -3.1%	$11.00 +254.8%	+41.8%	$26.69M	$7.53M	N/A	60	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNFA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TNF Pharmaceuticals (TNFA) Competitors

TNFA vs. BRNS, BCTX, CPHI, EVAX, and PLRZ

How does TNF Pharmaceuticals compare to Barinthus Biotherapeutics?

Summary

How does TNF Pharmaceuticals compare to Briacell Therap?

Summary

How does TNF Pharmaceuticals compare to China Pharma?

Summary

How does TNF Pharmaceuticals compare to Evaxion A/S?

Summary

How does TNF Pharmaceuticals compare to Polyrizon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNFA vs. The Competition

TNF Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TNF Pharmaceuticals (TNFA) Competitors

TNFA vs. BRNS, BCTX, CPHI, EVAX, and PLRZ

How does TNF Pharmaceuticals compare to Barinthus Biotherapeutics?

Do analysts rate BRNS or TNFA?

Does the media refer more to BRNS or TNFA?

Is BRNS or TNFA more profitable?

Do institutionals and insiders believe in BRNS or TNFA?

Which has preferable valuation & earnings, BRNS or TNFA?

Which has more volatility and risk, BRNS or TNFA?

Summary

How does TNF Pharmaceuticals compare to Briacell Therap?

Does the media favor BCTX or TNFA?

Do insiders & institutionals believe in BCTX or TNFA?

Which has preferable valuation and earnings, BCTX or TNFA?

Do analysts rate BCTX or TNFA?

Is BCTX or TNFA more profitable?

Which has more risk and volatility, BCTX or TNFA?

Summary

How does TNF Pharmaceuticals compare to China Pharma?

Do analysts rate CPHI or TNFA?

Is CPHI or TNFA more profitable?

Do institutionals and insiders hold more shares of CPHI or TNFA?

Which has higher earnings & valuation, CPHI or TNFA?

Does the media favor CPHI or TNFA?

Which has more volatility & risk, CPHI or TNFA?

Summary

How does TNF Pharmaceuticals compare to Evaxion A/S?

Is TNFA or EVAX more profitable?

Do institutionals and insiders believe in TNFA or EVAX?

Which has more volatility & risk, TNFA or EVAX?

Does the media prefer TNFA or EVAX?

Do analysts prefer TNFA or EVAX?

Which has stronger earnings & valuation, TNFA or EVAX?

Summary

How does TNF Pharmaceuticals compare to Polyrizon?

Is PLRZ or TNFA more profitable?

Do analysts prefer PLRZ or TNFA?

Do institutionals & insiders hold more shares of PLRZ or TNFA?

Which has more volatility and risk, PLRZ or TNFA?

Does the media favor PLRZ or TNFA?

Which has higher earnings & valuation, PLRZ or TNFA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNFA vs. The Competition

TNF Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools